RENAL OUTCOMES IN DIABETIC KIDNEY PATIENTS TREATED WITH GLP1 AGONIST RECEPTORS VS SGLT2 INHIBITORS

被引：0
|
作者：
Maroto, Alba [1 ]
Vidas, Maria Marques [1 ]
Sanz, Ignacio [1 ]
Lopez, Paula [1 ]
Portoles, Jose' M. [1 ]
机构：
[1] Hosp Univ Puerta Hierro Majadahonda Madrid, Nephrol, Majadahonda, Spain
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2020年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
P1009
引用
下载
收藏
页码：1331 / 1331
页数：1
相关论文
共 50 条
  • [21] SGLT2 INHIBITOR AND GLP1 AGONIST USE ARE ASSOCIATED WITH REDUCED RISK OF INCIDENT PULMONARY HYPERTENSION IN PATIENTS REFERRED FOR ECHOCARDIOGRAPHY
    King, Nicholas
    Huang, Shi
    Annis, Jeffrey
    Brittain, Evan L.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 1914 - 1914
  • [22] Making a case for the combined use of SGLT2 inhibitors and GLP1 receptor agonists for cardiorenal protection
    Sridhar, Vikas S.
    Dubrofsky, Lisa
    Boulet, Jacinthe
    Cherney, David Z.
    JORNAL BRASILEIRO DE NEFROLOGIA, 2020, 42 (04): : 467 - 477
  • [23] Decision Algorithm for Prescribing SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease
    Li, Jiahua
    Albajrami, Oltjon
    Zhuo, Min
    Hawley, Chelsea E.
    Paik, Julie M.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2020, 15 (11): : 1678 - 1688
  • [24] DIABETES MEDICATION DECISION SUPPORT IN GIM: INCREASING PRESCRIPTIONS OF SGLT2 INHIBITORS AND GLP1 AGONISTS
    Hilgeman, Brian C.
    Kastner, Mandy
    MacKinney, Theodore
    Maguire, Ann
    Mendez, Carlos
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2021, 36 (SUPPL 1) : S413 - S413
  • [25] SGLT2 Inhibitors vs GLP-1 Receptor Agonists and Clinical Outcomes in Patients With Diabetes With/Without Atrial Fibrillation
    Chan, Yi-Hsin
    Chao, Tze-Fan
    Chen, Shao-Wei
    Lee, Hsin-Fu
    Li, Pei-Ru
    Yeh, Yung-Hsin
    Kuo, Chi-Tai
    See, Lai-Chu
    Lip, Gregory Y. H.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2024, 109 (10): : 2617 - 2629
  • [26] Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes
    Edmonston, Daniel
    Mulder, Hillary
    Lydon, Elizabeth
    Chiswell, Karen
    Lampron, Zachary
    Shay, Christina
    Marsolo, Keith
    Shah, Raj C.
    Jones, W. Schuyler
    Gordon, Howard
    Hwang, Wenke
    Ayoub, Isabella
    Ford, Daniel
    Chamberlain, Alanna
    Rao, Ajaykumar
    Fonseca, Vivian
    Chang, Alexander
    Ahmad, Faraz
    Hung, Adriana
    Hunt, Kelly
    Butler, Javed
    Bosworth, Hayden B.
    Pagidipati, Neha
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 84 (08) : 696 - 708
  • [27] SGLT2 inhibitors to prevent diabetic kidney disease
    Fioretto, Paola
    Vettor, Roberto
    Pontremoli, Roberto
    LANCET DIABETES & ENDOCRINOLOGY, 2020, 8 (01): : 4 - 5
  • [28] Use of SGLT2 Inhibitors vs GLP-1 RAs and Anemia in Patients With Diabetes and CKD
    Hu, Jia-Chian
    Shao, Shih-Chieh
    Tsai, Daniel Hsiang-Te
    Chuang, Albert Tzu-Ming
    Liu, Kuan-Hung
    Lai, Edward Chia-Cheng
    JAMA NETWORK OPEN, 2024, 7 (03) : E240946
  • [29] SGLT2 inhibitors: diabetic kidney disease and beyond
    Staruschenko, Alexander
    Bhalla, Vivek
    Rangaswami, Janani
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2020, 319 (05) : F780 - F781
  • [30] Comparative Effectiveness of SGLT2 Inhibitors vs. GLP-1 Agonists
    Poonawalla, Insiya
    Bowe, Andy
    Tindal, Michael
    Meah, Yunus A.
    Schwab, Phil
    DIABETES, 2020, 69
12345